In addition, DPP-4 acts to inhibit glucagon-like peptide-1 (GLP-1) potentially having a negative downstream effect on this target which is currently being investigated with GLP-1 agonists for the treatment of AD in two phase 3 clinical trials: evoke (NCT04777396) and evoke+ (NCT04777409) [45]. This evidence concerns the gene GCG and Alzheimer disease.